<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03181360</url>
  </required_header>
  <id_info>
    <org_study_id>2015/1070/REC North</org_study_id>
    <secondary_id>2014-000096-80</secondary_id>
    <nct_id>NCT03181360</nct_id>
  </id_info>
  <brief_title>Tenecteplase in Wake-up Ischaemic Stroke Trial</brief_title>
  <acronym>TWIST</acronym>
  <official_title>Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST). A Randomised-controlled Trial of Thrombolytic Treatment With Tenecteplase for Acute Ischaemic Stroke Upon Awakening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UiT The Arctic University of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Royal Norwegian Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Health Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is a leading causes of death and disability. At least 20% of strokes occur during&#xD;
      sleep, so- called 'wake up stroke'. Thrombolysis with the clot-busting drug alteplase is&#xD;
      effective for acute ischaemic stroke, provided that it is given within 4.5 hours of symptom&#xD;
      onset. Patients with wake-up stroke are currently ineligible for clot-busting therapy.&#xD;
      Previous studies indicate that many wake-up strokes occur just before awakening.&#xD;
&#xD;
      In this study, patients with wake-up stroke will be randomized to thrombolysis with&#xD;
      tenecteplase and best standard treatment or to best standard treatment without thrombolysis.&#xD;
      Tenecteplase has several potential advantages over alteplase, including very rapid action and&#xD;
      that it can be given as a single injection. Prior to thrombolysis, a brain scan must be done&#xD;
      to exclude bleeding or significant brain damage as a result from the stroke. We will use a CT&#xD;
      scan to inform this decision. CT is used as a routine examination in all stroke patients.&#xD;
      Other studies testing clot-busting treatment in wake-up stroke are using alteplase and more&#xD;
      complex brain scans, which are not routinely available in the emergency situation in all&#xD;
      hospitals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      One in five strokes occur during sleep, but patients with &quot;wake-up&quot; stroke are not given&#xD;
      thrombolytic therapy because time of stroke onset is unknown. On-going trials are testing&#xD;
      alteplase, and use MRI techniques for selection of patients. Tenecteplase has many&#xD;
      pharmacological advantages over alteplase: greater fibrin specificity, very rapid action,&#xD;
      longer half-life, and single bolus administration. In addition, patient selection based on&#xD;
      MRI findings risks excluding many patients that might otherwise benefit. TWIST will test&#xD;
      tenecteplase and will not use MRI techniques for selection of patients. Plain CT and CT&#xD;
      angiography (if possible) will be performed before randomisation, and CT perfusion will be&#xD;
      performed at selected centres, as part of a sub-study.&#xD;
&#xD;
      Study design: TWIST is an international, multi-centre, randomised, open-label,&#xD;
      blinded-endpoint trial of tenecteplase for acute ischaemic 'wake-up' stroke.&#xD;
&#xD;
      Study questions:&#xD;
&#xD;
        1. Can tenecteplase given &lt;4.5 hours of awakening improve functional outcome at 3 months?&#xD;
&#xD;
        2. Can findings on cerebral plain CT and CT angiography (and CT perfusion, at selected&#xD;
           centres) identify patients who benefit from such treatment, compared to other patients?&#xD;
&#xD;
      Patients eligible for treatment who are able to receive tenecteplase within 4.5 hours of&#xD;
      waking, will be randomly allocated to treatment with tenecteplase in addition to best&#xD;
      standard treatment, versus best standard treatment.&#xD;
&#xD;
      Randomisation and treatment: Central randomisation (over the internet) to tenecteplase 0.25&#xD;
      mg/mg i.v. (maximum dose 25 mg) plus best medical treatment vs. best medical treatment alone.&#xD;
&#xD;
      Imaging: All patients will undergo CT and CT angiography (CTA, if possible) before&#xD;
      randomisation and on day 2. CT perfusion (CTP) will be performed at selected centres, as part&#xD;
      of a sub-study.&#xD;
&#xD;
      Follow-up and primary effect variable: Centralised follow-up via telephone or mail at 3&#xD;
      months. The primary effect variable is functional outcome (modified Rankin Scale score).&#xD;
&#xD;
      Study size and centers: 600 patients from centers in Norway, Sweden, Denmark, Finland,&#xD;
      Estonia, Latvia, Lithuania, United Kingdom, Switzerland and New Zealand.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional outcome at 3 months.</measure>
    <time_frame>3 months</time_frame>
    <description>Functional outcome will be assessed by the modified Rankin Scale (mRS), values 0-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial haemorrhage during the first 7 days.</measure>
    <time_frame>First 7 days</time_frame>
    <description>Symptoms (neurological deterioration, new headache, new acute hypertension, new nausea or vomiting, or sudden decrease in conscious level).&#xD;
Intracranial haemorrhage on brain MRI or CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic intracranial haemorrhage during the first 7 days.</measure>
    <time_frame>First 7 days</time_frame>
    <description>Intracranial haemorrhage on brain MRI or CT without: neurological deterioration, new headache, new acute hypertension, new nausea or vomiting or sudden decrease in consciousness level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent ischaemic stroke during the first 7 days</measure>
    <time_frame>First 7 days</time_frame>
    <description>Neurological deterioration (increase of ≥2 on NIHSS, after exclusion of other causes for neurological deterioration) occurring after 72 hours will be considered as a recurrent stroke. A recurrent stroke will be classified as ischaemic if imaging has excluded haemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from all cause</measure>
    <time_frame>First 7 days</time_frame>
    <description>Death will be classified according to cause:&#xD;
Initial stroke&#xD;
Recurrent stroke&#xD;
Myocardial infarction&#xD;
Pneumonia&#xD;
Other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from all cause</measure>
    <time_frame>3 months</time_frame>
    <description>Death will be classified according to cause:&#xD;
Initial stroke&#xD;
Recurrent stroke&#xD;
Myocardial infarction&#xD;
Pneumonia&#xD;
Other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index score</measure>
    <time_frame>3 months</time_frame>
    <description>Ordinal scale for measuring performance in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Score (EQ-5D)</measure>
    <time_frame>3 months</time_frame>
    <description>Measure of health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Examination</measure>
    <time_frame>3 months</time_frame>
    <description>30-point questionnaire for measurement of cognitive impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-economic variables</measure>
    <time_frame>3 months</time_frame>
    <description>Costs related to length of hospital stay, nursing home care after discharge, re-hospitalisations during first 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Functional outcome assessed by dichotomized mRS; values 0-1 vs 2-6.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Stroke, Acute</condition>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenecteplase + Best standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No tenecteplase + Best standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.</description>
    <arm_group_label>Tenecteplase</arm_group_label>
    <other_name>Metalyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Best standard treatment</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stroke symptoms on awakening that were not present before sleep&#xD;
&#xD;
          -  Clinical diagnosis of stroke with limb weakness with NIHSS score &gt;=3, or dysphasia&#xD;
&#xD;
          -  Treatment with tenecteplase is possible within 4.5 hours of awakening&#xD;
&#xD;
          -  Written consent from the patient, non-written consent from the patient (witnessed by&#xD;
             non-participating health care personnel), or written consent from the nearest family&#xD;
             member&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  NIHSS score &gt;25 or NIHSS consciousness score &gt;2, or seizures during stroke onset&#xD;
&#xD;
          -  Findings on plain CT that indicate that the patient is unlikely to benefit from&#xD;
             treatment:&#xD;
&#xD;
               -  Infarction comprising more than &gt;1/3 of the middle cerebral artery territory on&#xD;
                  plain CT or CT perfusion&#xD;
&#xD;
               -  Intracranial haemorrhage, structural brain lesions which can mimic stroke (e.g&#xD;
                  cerebral tumour)&#xD;
&#xD;
          -  Active internal bleeding of high risk of bleeding, e.g.:&#xD;
&#xD;
               -  Major surgery, trauma or gastrointestinal or urinary tract haemorrhage within the&#xD;
                  previous 21 days, or arterial puncture at a non-compressible site within the&#xD;
                  previous 7 days&#xD;
&#xD;
               -  Any known defect in coagulation, e.g. current use of vitamin K antagonist with an&#xD;
                  INR &gt;1.7 or prothrombin time &gt;15 seconds, or use of direct thrombin inhibitors or&#xD;
                  direct factor Xa inhibitors during the last 24 hours (unless reversal of effect&#xD;
                  can be achieved by agents such as idarucizumab) or with elevated sensitive&#xD;
                  laboratory tests (such as activated partial thromboplastin time (aPTT),&#xD;
                  international normalized ratio (INR), platelet count, ecarin clotting time,&#xD;
                  thrombin time (TT), or appropriate factor Xa activity assays), or heparins during&#xD;
                  the last 24 hours or with an elevated aPTT greater than the upper limit of normal&#xD;
&#xD;
               -  Known defect of clotting or platelet function or platelet count below 100,000/mm3&#xD;
                  (but patients on antiplatelet agents can be included)&#xD;
&#xD;
               -  Ischaemic stroke or myocardial infarction in previous 3 months, previous&#xD;
                  intracranial haemorrhage, severe traumatic brain injury or intracranial or&#xD;
                  intraspinal operation in previous 3 months, or known intracranial neoplasm,&#xD;
                  arteriovenous malformation or aneurysm&#xD;
&#xD;
          -  Contraindications to tenecteplase, e.g., acute bacterial endocarditis or pericarditis;&#xD;
             acute pancreatitis; severe hepatic dysfunction, including hepatic failure, cirrhosis,&#xD;
             portal hypertension; active hepatitis; systemic cancer with increased bleeding risk;&#xD;
             haemostatic defect including secondary to severe hepatic, renal disease; organ biopsy;&#xD;
             prolonged cardiopulmonary resuscitation &gt; 2 min (within 2 weeks)&#xD;
&#xD;
          -  Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg),&#xD;
             despite blood pressure lowering treatment&#xD;
&#xD;
          -  Blood glucose &lt;2.7 or &gt;20.0 mmol/L (use of finger-stick measurement devices is&#xD;
             acceptable)&#xD;
&#xD;
          -  Pregnancy, positive pregnancy test, childbirth during last 10 days, or breastfeeding.&#xD;
             In any woman of childbearing potential, a pregnancy test must be performed and the&#xD;
             result assessed before trial entry&#xD;
&#xD;
          -  Other serious or life-threatening disease before the stroke: severe mental or physical&#xD;
             disability (e.g. Mini Mental Status score &lt;20, or mRS score ≥3), or life expectancy&#xD;
             less than 12 months&#xD;
&#xD;
          -  Patient unavailability for follow-up (e.g. no fixed address)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellisiv B Mathiesen</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of North Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melinda B Roaldsen, MD</last_name>
    <phone>+47 77627120</phone>
    <email>melinda.b.roaldsen@uit.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnethe Eltoft, MD, PhD</last_name>
    <phone>+47 77698906</phone>
    <email>agnethe.eltoft@unn.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Silver, MD</last_name>
      <phone>508-334-5989</phone>
      <email>Brian.Silver@umassmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Brian Silver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bispebjerg hospital</name>
      <address>
        <city>København</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanne Christensen, MD, PhD</last_name>
      <phone>+45 38 63 50 00</phone>
      <email>hanne.krarup.christensen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ægidius</last_name>
      <email>Karen.Lehrmann.AEgidius@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Karen L. Ægidius, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pärnu Hospital</name>
      <address>
        <city>Pärnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Antsov, MD</last_name>
      <phone>+3724494800</phone>
      <email>katrin.antsov@ph.ee</email>
    </contact>
    <investigator>
      <last_name>Katrin Antsov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Tallin Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toomas Toomsoo, MD</last_name>
      <phone>+3726661900</phone>
      <email>toomas.toomsoo@itk.ee</email>
    </contact>
    <investigator>
      <last_name>Toomas Toomsoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Tallin Central Hospital</name>
      <address>
        <city>Tallin</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Gross-Paju, MD</last_name>
      <phone>+3726261314</phone>
      <email>katrin.gross-paju@keskhaigla.ee</email>
    </contact>
    <investigator>
      <last_name>Katrin Gross-Paju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Clinic</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janika Kõrv</last_name>
      <phone>+372 731 811</phone>
      <email>janika.korv@kliinikum.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Satakunta Central Hospital</name>
      <address>
        <city>Pori</city>
        <state>Satakunta</state>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juha Puustinen, MD</last_name>
      <phone>+358262771</phone>
      <email>juha.puustinen@satshp.fi</email>
    </contact>
    <investigator>
      <last_name>Juha Puustinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Putaala, Md, PhD</last_name>
      <email>jukka.putaala@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siun sote - Joint municipal authority for North Karelia social and health services</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirpa Kaipiainen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jussi Sipilä, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pohjois-Kymen sairaala</name>
      <address>
        <city>Kouvola</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tero Tapiola</last_name>
      <phone>+358 5 352000</phone>
      <email>tero.tapiola@kouvola.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital in Vaasa</name>
      <address>
        <city>Vaasa</city>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Saarinen, MD</last_name>
      <phone>+35863231111</phone>
      <email>jukka.saarinen@vshp.fi</email>
    </contact>
    <investigator>
      <last_name>Jukka Saarinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riga East University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aleksejs Višņakovs</last_name>
    </contact>
    <investigator>
      <last_name>Guntis Karelis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alytus S. Kudirkos Hospital</name>
      <address>
        <city>Alytus</city>
        <zip>62114</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juknelis Kestutis, MD</last_name>
      <phone>+37031556301</phone>
      <email>jukneliskestutis@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Juknelis Kestutis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daiva Rastenyte, MD</last_name>
      <phone>+37037326467</phone>
      <email>daiva.rastenyte@kaunoklinikos.lt</email>
    </contact>
    <investigator>
      <last_name>Daiva Rastenyte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klaipeda Seamen's Hospital</name>
      <address>
        <city>Klaipėda</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robertas Urbutis, MD</last_name>
      <phone>46 491009</phone>
      <phone_ext>+370</phone_ext>
      <email>rourb@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Robertas Urbutis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Republican Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-04130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandras Vilionskis, MD</last_name>
      <email>aleksandras.vilionskis@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalius Jatuzis, MD, PhD</last_name>
      <phone>+370 5 236 5000</phone>
      <email>dalius.jatuzis@santa.lt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teddy Wu, MD, PhD</last_name>
      <email>teddy.wu@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>Teddy Wu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sørlandet sykehus HF Arendal</name>
      <address>
        <city>Arendal</city>
        <zip>4838</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Drammen sykehus Vestre Viken HF</name>
      <address>
        <city>Drammen</city>
        <zip>N-3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl-Friedrich Amthor, MD</last_name>
      <phone>+47 91503525</phone>
      <email>karamt@vestreviken.no</email>
    </contact>
    <investigator>
      <last_name>Karl-Friedrich Amthor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sørlandet Sykehus HF Flekkefjord</name>
      <address>
        <city>Flekkefjord</city>
        <zip>N-4400</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Van Lessen, MD</last_name>
      <phone>+47 91503738</phone>
      <email>rita.van.lessen@sshf.no</email>
    </contact>
    <investigator>
      <last_name>Rita Van Lessen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Førde HF</name>
      <address>
        <city>Førde</city>
        <zip>N-6807</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Stankiewicz, MD</last_name>
      <phone>+47 57839000</phone>
      <email>magdalena.stankiewicz@helse-forde.no</email>
    </contact>
    <investigator>
      <last_name>Magdalena Stankiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nordlandssykehuset Lofoten Gravdal</name>
      <address>
        <city>Gravdal</city>
        <zip>N-8372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Heermann, MD</last_name>
      <phone>+47 76060100</phone>
      <email>bettina.heermann@nordlandssykehuset.no</email>
    </contact>
    <investigator>
      <last_name>Bettina Heermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Finnmark Hammerfest</name>
      <address>
        <city>Hammerfest</city>
        <zip>N-9601</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svein A Størdahl, MD</last_name>
      <phone>+47 78421000</phone>
      <email>svein.are.stordal@finnmarkssykehuset.no</email>
    </contact>
    <investigator>
      <last_name>Svein A Størdahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway, Harstad</name>
      <address>
        <city>Harstad</city>
        <zip>9480</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Fjellstad, MD</last_name>
      <phone>+47 07766</phone>
      <email>maria.serafia.fjellstad@unn.no</email>
    </contact>
    <investigator>
      <last_name>Maria Fjellstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Finnmark HF Kirkenes</name>
      <address>
        <city>Kirkenes</city>
        <zip>N-9900</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tonje A Melum, MD</last_name>
      <phone>+47 78421000</phone>
      <email>tonje.anita.melum@finnmarkssykehuset.no</email>
    </contact>
    <investigator>
      <last_name>Tonje A Melum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sørlandet sykehus Kristiansand HF</name>
      <address>
        <city>Kristiansand</city>
        <zip>N-4604</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnstein Tveiten, MD, PhD</last_name>
      <phone>+47 38074000</phone>
      <email>arnstein.tveiten@sshf.no</email>
    </contact>
    <contact_backup>
      <last_name>Mary-Helen Søyland, MD</last_name>
      <phone>+47 38074000</phone>
      <email>mary-helen.soyland@sshf.no</email>
    </contact_backup>
    <investigator>
      <last_name>Arnstein Tveiten, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sykehuset Levanger</name>
      <address>
        <city>Levanger</city>
        <zip>N-7601</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Akershus universitetssykehus (Ahus)</name>
      <address>
        <city>Lørenskog</city>
        <zip>N-1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Reichenbach, MD</last_name>
      <phone>+47 91502900</phone>
      <email>antje.reichenbach@ahus.no</email>
    </contact>
    <investigator>
      <last_name>Antje Reichenbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helgelandssykehuset Mosjøen</name>
      <address>
        <city>Mosjøen</city>
        <zip>N-8651</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway, Narvik</name>
      <address>
        <city>Narvik</city>
        <zip>N-8504</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arne Haavik, MD</last_name>
      <phone>+47 76968000</phone>
      <email>arne.haavik@unn.no</email>
    </contact>
    <investigator>
      <last_name>Arne Haavik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bærum sykehus Vestre Viken HF</name>
      <address>
        <city>Sandvika</city>
        <zip>N-1346</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Håkon Ihle-Hansen, MD</last_name>
      <phone>06780</phone>
      <phone_ext>+47</phone_ext>
      <email>haaihl@vestreviken.no</email>
    </contact>
    <investigator>
      <last_name>Håkon Ihle-Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sykehuset Telemark Skien</name>
      <address>
        <city>Skien</city>
        <zip>N-3710</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Håkon Tobro, MD</last_name>
      <phone>+47 35003500</phone>
      <email>haa.tob@sthf.no</email>
    </contact>
    <investigator>
      <last_name>Håkon Tobro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssjukehus</name>
      <address>
        <city>Stavanger</city>
        <zip>N-4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway, Tromsø</name>
      <address>
        <city>Tromsø</city>
        <zip>N-9019</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Einar Bugge, MD, PhD</last_name>
      <email>einar.bugge@unn.no</email>
    </contact>
    <contact_backup>
      <last_name>Melinda B Roaldsen, MD</last_name>
      <phone>+47 77627120</phone>
      <email>melinda.b.roaldsen@uit.no</email>
    </contact_backup>
    <investigator>
      <last_name>Agnethe Eltoft, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gitta Rohweder, MD</last_name>
      <phone>+47 81555815</phone>
      <email>gitta.rohweder@stolav.no</email>
    </contact>
    <contact_backup>
      <last_name>Bent Indredavik, MD, PhD</last_name>
      <phone>+47 81555815</phone>
      <email>bent.indredavik@ntnu.no</email>
    </contact_backup>
    <investigator>
      <last_name>Gitta Rohweder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ålesund sjukehus Helse Møre og Romsdal</name>
      <address>
        <city>Ålesund</city>
        <zip>N-6026</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yngve M Seljeseth, MD</last_name>
      <phone>+47 70105000</phone>
      <email>Yngve.Muller.Seljeseth@helse-mr.no</email>
    </contact>
    <investigator>
      <last_name>Yngve M Seljeseth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Erik Karlsson, MD</last_name>
      <phone>+46 31 342 10 00</phone>
      <email>jan-erik.karlsson@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hässleholm Sjukhus</name>
      <address>
        <city>Hässleholm</city>
        <zip>281 25</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Esbjörnsson, MD</last_name>
      <phone>+46 0451 29 60 60</phone>
      <email>Magnus.Esbjornsson@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital Karlstad</name>
      <address>
        <city>Karlstad</city>
        <zip>65230</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Andler, MD</last_name>
      <phone>+4654615000</phone>
      <email>Felix.Andler@liv.se</email>
    </contact>
    <investigator>
      <last_name>Felix Andler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gunnar Andsberg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gunnar Andsberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper Petersson, MD, PhD</last_name>
      <phone>+46 40331000</phone>
      <email>jesper.petersson@skane.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skaraborg Hospital Skövde</name>
      <address>
        <city>Skövde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Cederin, MD</last_name>
      <phone>+46500431000</phone>
      <email>bjorn.cederin@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Björn Cederin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska sjukhuset</name>
      <address>
        <city>Solna</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Saint Göran Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Mathé, MD</last_name>
      <phone>+46858701000</phone>
      <email>jan.mathe@capiostgoran.se</email>
    </contact>
    <investigator>
      <last_name>Jan Mathé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabet Rooth, MD</last_name>
      <phone>+46812355000</phone>
      <email>elisabet.anggardh-rooth@sll.se</email>
    </contact>
    <investigator>
      <last_name>Elisabet Rooth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Sjölin, MD</last_name>
      <phone>+46 18 611 00 00</phone>
      <email>karl.sjolin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ängelholm Hospital</name>
      <address>
        <city>Ängelholm</city>
        <zip>26281</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Björn Hedström, MD</last_name>
      <phone>+4643181000</phone>
      <email>Bjorn.Hedstrom@skane.se</email>
    </contact>
    <investigator>
      <last_name>Björn Hedström, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian M De Marchis, MD, MSc</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>gian.demarchis@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Ouest Lémanique</name>
      <address>
        <city>Nyon</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Niederhauser, MD</last_name>
      <email>julien.niederhauser@ghol.ch</email>
    </contact>
    <investigator>
      <last_name>Julien Niederhauser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinderfields Hospital</name>
      <address>
        <city>Wakefield</city>
        <state>Mid Yorkshire</state>
        <zip>WF1 4DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Carpenter, MD</last_name>
      <phone>48118110</phone>
      <phone_ext>+4484</phone_ext>
      <email>michael.carpenter@midyorks.nhs.net</email>
    </contact>
    <investigator>
      <last_name>Michael Carpenter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northumbria Specialist Emergency Care Hospital</name>
      <address>
        <city>Cramlington</city>
        <state>Northumberland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Garside</last_name>
      <email>Mark.Garside@northumbria-healthcare.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Garside, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Joan Macleod, MD</last_name>
      <phone>+44 345 456 6000</phone>
      <email>m.j.macleod@abdn.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mary Joan Macleod, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arrowe Park</name>
      <address>
        <city>Birkenhead</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Davies</last_name>
      <email>ruth.davies@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Ruth Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Willmot</last_name>
      <email>mark.willmot@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Mark Willmot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemoth and Christchurch Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Hopper, MD</last_name>
      <phone>+441202 303626</phone>
      <email>oliver.hopper@rbch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Oliver Hopper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Warburton, MD</last_name>
      <phone>+44 1223 245151</phone>
      <email>elizabeth.warburton@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Warburton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Countess of Chester Hospital NHS Foundation Trust</name>
      <address>
        <city>Chester</city>
        <zip>CH2 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kausik Chatterjee</last_name>
      <phone>44365000</phone>
      <phone_ext>+4412</phone_ext>
      <email>kausikchatterjee@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Kausik Chatterjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Usman Ghani, MD</last_name>
      <email>usman.ghani@uhcw.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Usman Ghani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE 22 3 NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy England, MD</last_name>
      <phone>+441332340131</phone>
      <email>timothy.england@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Timothy England, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Whiteley, MD</last_name>
      <phone>+44 131 536 1000</phone>
      <email>william.whiteley@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>William Whiteley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin James, MD</last_name>
      <phone>+44 1392 411611</phone>
      <email>martinjames@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Martin James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dipankar Dutta</last_name>
      <email>dipankar.dutta@glos.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Dipankar Dutta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calderdale Royal Infirmary</name>
      <address>
        <city>Halifax</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Nair</last_name>
      <email>Anand.Nair@cht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anand Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull University Teaching Hospital</name>
      <address>
        <city>Kingston upon Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Clarkson</last_name>
      <email>EmmaP.Clarkson@hey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Emma Clarkson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasileios Papavasileiou</last_name>
      <email>v.papavasileiou@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Vasileios Papavasileiou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thompson G Robinson, MD, PhD</last_name>
      <email>tgr2@le.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Manning, MD</last_name>
      <email>lm313@le.ac.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aravind Manoj</last_name>
      <email>aravind.manoj@rlbuht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Aravind Manoj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Perry, MD</last_name>
      <phone>+44 20 3456 7890</phone>
      <email>richard.perry@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Perry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King´s College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lalit Kalra, MD</last_name>
      <phone>+44 20 3299 9000</phone>
      <email>lalit.kalra@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Lalit Kalra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Georges Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry Moynihan, MD</last_name>
      <phone>+44 20 8672 1255</phone>
      <email>Barry.moynihan@stgeorges.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Barry Moynihan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omid Halse, MD</last_name>
      <phone>+44 20 3311 1234</phone>
      <email>Omid.Halse@imperial.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Omid Halse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Evans</last_name>
      <email>rachel.evans60@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Rachel Evans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luton and Dunstable University Hospital</name>
      <address>
        <city>Luton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sakthivel Sethuraman</last_name>
      <email>sakthivel.sethuraman@ldh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sakthivel Sethuraman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital</name>
      <address>
        <city>Morriston</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mushtaq Wani, MD</last_name>
      <phone>+44 1792 702222</phone>
      <email>Mushtaq.Wani@wales.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mushtaq Wani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Dixit, MD</last_name>
      <phone>+441912336161</phone>
      <email>Anand.dixit@nuth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anand Dixit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Bath, MD</last_name>
      <phone>+441159691169</phone>
      <email>Philip.bath@nottingham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Philip Bath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bharath Cheripelli</last_name>
      <email>bharath.cheripelli@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Bharath Cheripelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southhampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Marigold</last_name>
      <email>james.marigold@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Marigold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Girish Muddegowda</last_name>
      <email>girish.muddegowda2@uhnm.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Girish Muddegowda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dumin Karunatilake, MD</last_name>
      <email>dumin.karunatilake@tst.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Dumin Karunatilake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalid Rashed, MD</last_name>
      <phone>+44 1935 475122</phone>
      <email>khalid.rashed@ydh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Khalid Rashed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>wake-up</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>tenecteplase</keyword>
  <keyword>computed tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03181360/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

